{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:19:18Z","timestamp":1775841558625,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2020\/13956-9"],"award-info":[{"award-number":["2020\/13956-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["141262\/2021-4"],"award-info":[{"award-number":["141262\/2021-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-03057-z","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T10:16:23Z","timestamp":1731665783000},"page":"199-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of antiplatelets, anticoagulants and cyclic nucleotide stimulators on neutrophil extracellular traps (NETs) and inflammatory markers during COVID-19"],"prefix":"10.1007","volume":"58","author":[{"given":"Jos\u00e9 D.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gislaine","family":"Vieira-Damiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia Q.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme R.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila O.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna C.","family":"Jacintho-Robison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna M.","family":"Mazetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erich V.","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fab\u00edola Z.","family":"Monica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7908-9073","authenticated-orcid":false,"given":"Fernanda A.","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"3057_CR1","doi-asserted-by":"publisher","unstructured":"Brinkmann V et al (2004) Neutrophil extracellular traps kill bacteria. Science 303(5663):1532\u20131535. ISSN 0036-8075. https:\/\/doi.org\/10.1126\/science.1092385","DOI":"10.1126\/science.1092385"},{"issue":"2","key":"3057_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nri.2017.105","volume":"18","author":"V Papayannopoulos","year":"2018","unstructured":"Papayannopoulos V (2018) Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 18(2):134\u2013147. https:\/\/doi.org\/10.1038\/nri.2017.105","journal-title":"Nat Rev Immunol"},{"key":"3057_CR3","volume-title":"NETosis: immunity, pathogenesis and therapeutics","author":"G Rai","year":"2019","unstructured":"Rai G (2019) NETosis: immunity, pathogenesis and therapeutics. Elsevier, London"},{"issue":"4","key":"3057_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/JLB.3RU0620-375R","volume":"110","author":"C Tan","year":"2021","unstructured":"Tan C, Aziz M, Wang P (2021) The vitals of NETs. J Leukoc Biol 110(4):797\u2013808. https:\/\/doi.org\/10.1002\/JLB.3RU0620-375R","journal-title":"J Leukoc Biol"},{"key":"3057_CR5","doi-asserted-by":"publisher","unstructured":"Demkow U (2023) Molecular mechanisms of neutrophil extracellular trap (NETs) degradation. Int J Mol Sci 24(5). https:\/\/doi.org\/10.3390\/ijms24054896","DOI":"10.3390\/ijms24054896"},{"key":"3057_CR6","doi-asserted-by":"publisher","unstructured":"Denning NL et al (2019) DAMPs and NETs in sepsis. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.02536","DOI":"10.3389\/fimmu.2019.02536"},{"key":"3057_CR7","doi-asserted-by":"publisher","first-page":"963955","DOI":"10.3389\/fimmu.2022.963955","volume":"13","author":"CL Zhu","year":"2022","unstructured":"Zhu CL et al (2022) Dysregulation of neutrophil death in sepsis. Front Immunol 13:963955. https:\/\/doi.org\/10.3389\/fimmu.2022.963955","journal-title":"Front Immunol"},{"issue":"2","key":"3057_CR8","doi-asserted-by":"publisher","first-page":"e0148142","DOI":"10.1371\/journal.pone.0148142","volume":"11","author":"PG Czaikoski","year":"2016","unstructured":"Czaikoski PG et al (2016) Neutrophil Extracellular traps induce organ damage during experimental and clinical sepsis. PLoS ONE 11(2):e0148142. https:\/\/doi.org\/10.1371\/journal.pone.0148142","journal-title":"PLoS ONE"},{"key":"3057_CR9","doi-asserted-by":"publisher","unstructured":"Funchal GA et al (2015) Respiratory syncytial virus fusion protein promotes TLR-4-dependent neutrophil extracellular trap formation by human neutrophils. PloS One 10(4). https:\/\/doi.org\/10.1371\/journal.pone.0124082","DOI":"10.1371\/journal.pone.0124082"},{"issue":"1","key":"3057_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ajpath.2011.03.013","volume":"179","author":"T Narasaraju","year":"2011","unstructured":"Narasaraju T et al (2011) Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol 179(1):199\u2013210. https:\/\/doi.org\/10.1016\/j.ajpath.2011.03.013","journal-title":"Am J Pathol"},{"key":"3057_CR11","doi-asserted-by":"publisher","unstructured":"Zuo Y et al (2020) Neutrophil extracellular traps in COVID-19. JCI Insight 5(11). ISSN 2379-3708. https:\/\/doi.org\/10.1172\/jci.insight.138999","DOI":"10.1172\/jci.insight.138999"},{"issue":"11","key":"3057_CR12","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1038\/s41418-021-00805-z","volume":"28","author":"M Ackermann","year":"2021","unstructured":"Ackermann M et al (2021) Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death Differ 28(11):3125\u20133139. https:\/\/doi.org\/10.1038\/s41418-021-00805-z","journal-title":"Cell Death Differ"},{"key":"3057_CR13","doi-asserted-by":"publisher","first-page":"902206","DOI":"10.3389\/fimmu.2022.902206","volume":"13","author":"E Ventura-Santana","year":"2022","unstructured":"Ventura-Santana E et al (2022) Neutrophil extracellular traps, sepsis and COVID-19\u2014a tripod stand. Front Immunol 13:902206. https:\/\/doi.org\/10.3389\/fimmu.2022.902206","journal-title":"Front Immunol"},{"key":"3057_CR14","doi-asserted-by":"publisher","unstructured":"Veras FP et al (2020) SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med 217(12). https:\/\/doi.org\/10.1084\/jem.20201129","DOI":"10.1084\/jem.20201129"},{"issue":"10","key":"3057_CR15","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","volume":"26","author":"AG Laing","year":"2020","unstructured":"Laing AG et al (2020) A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 26(10):1623\u20131635. https:\/\/doi.org\/10.1038\/s41591-020-1038-6","journal-title":"Nat Med"},{"issue":"10","key":"3057_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2020007008","volume":"136","author":"EA Middleton","year":"2020","unstructured":"Middleton EA et al (2020) Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136(10):1169\u20131179. https:\/\/doi.org\/10.1182\/blood.2020007008","journal-title":"Blood"},{"key":"3057_CR17","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-Jim\u00e9nez P et al (2023) Neutrophil extracellular traps and platelet activation for identifying severe episodes and clinical trajectories in COVID-19. Int J Mol Sci 24(7). https:\/\/doi.org\/10.3390\/ijms24076690","DOI":"10.3390\/ijms24076690"},{"issue":"2","key":"3057_CR18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.4049\/jimmunol.1700905","volume":"200","author":"S Gupta","year":"2018","unstructured":"Gupta S et al (2018) A High-throughput real-time imaging technique to quantify NETosis and distinguish mechanisms of cell death in human neutrophils. J Immunol 200(2):869\u2013879. https:\/\/doi.org\/10.4049\/jimmunol.1700905","journal-title":"J Immunol"},{"issue":"1","key":"3057_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.7150\/thno.49713","volume":"11","author":"JS Kim","year":"2021","unstructured":"Kim JS et al (2021) Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 11(1):316\u2013329. https:\/\/doi.org\/10.7150\/thno.49713","journal-title":"Theranostics"},{"key":"3057_CR20","doi-asserted-by":"publisher","unstructured":"Barnes BJ et al (2020) Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med 217(6). https:\/\/doi.org\/10.1084\/jem.20200652","DOI":"10.1084\/jem.20200652"},{"issue":"6","key":"3057_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2141","volume":"30","author":"EA Coomes","year":"2020","unstructured":"Coomes EA, Haghbayan H (2020) Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol 30(6):1\u20139","journal-title":"Rev Med Virol"},{"issue":"6","key":"3057_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/1744666X.2021.1919086","volume":"17","author":"N Potere","year":"2021","unstructured":"Potere N et al (2021) The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol 17(6):601\u2013618. https:\/\/doi.org\/10.1080\/1744666X.2021.1919086","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"3057_CR23","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle DM et al (2020) An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26(10):1636\u20131643. https:\/\/doi.org\/10.1038\/s41591-020-1051-9","journal-title":"Nat Med"},{"issue":"1","key":"3057_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12931-023-02650-9","volume":"25","author":"C de Diego","year":"2024","unstructured":"de Diego C et al (2024) What is the actual relationship between neutrophil extracellular traps and COVID-19 severity? A longitudinal study. Respir Res 25(1):48. https:\/\/doi.org\/10.1186\/s12931-023-02650-9","journal-title":"Respir Res"},{"issue":"1","key":"3057_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12931-023-02336-2","volume":"24","author":"FP Veras","year":"2023","unstructured":"Veras FP et al (2023) Targeting neutrophils extracellular traps (NETs) reduces multiple organ injury in a COVID-19 mouse model. Respir Res 24(1):66. https:\/\/doi.org\/10.1186\/s12931-023-02336-2","journal-title":"Respir Res"},{"key":"3057_CR26","doi-asserted-by":"publisher","unstructured":"Bliden K et al (2020) Abstract 16676: heightened platelet function: an unrecognized component of the covid hypercoagulability state. Circulation 142(Suppl_3):A16676\u2013A16676. https:\/\/doi.org\/10.1161\/circ.142.suppl_3.16676","DOI":"10.1161\/circ.142.suppl_3.16676"},{"key":"3057_CR27","doi-asserted-by":"publisher","first-page":"108468","DOI":"10.1016\/j.clim.2020.108468","volume":"216","author":"L Omarjee","year":"2020","unstructured":"Omarjee L et al (2020) Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19? Clin Immunol 216:108468. https:\/\/doi.org\/10.1016\/j.clim.2020.108468","journal-title":"Clin Immunol"},{"key":"3057_CR28","doi-asserted-by":"crossref","unstructured":"Lapponi MJ et al (2013) Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 345(3):430\u2013437. ISSN 0022-3565","DOI":"10.1124\/jpet.112.202879"},{"key":"3057_CR29","doi-asserted-by":"publisher","first-page":"551057","DOI":"10.3389\/fimmu.2020.551057","volume":"11","author":"T Wan","year":"2020","unstructured":"Wan T et al (2020) Acetylsalicylic acid promotes corneal epithelium migration by regulating neutrophil extracellular traps in alkali burn. Front Immunol 11:551057. https:\/\/doi.org\/10.3389\/fimmu.2020.551057","journal-title":"Front Immunol"},{"issue":"9","key":"3057_CR30","doi-asserted-by":"publisher","first-page":"e0161218","DOI":"10.1371\/journal.pone.0161218","volume":"11","author":"J Tilgner","year":"2016","unstructured":"Tilgner J et al (2016) Aspirin, but not tirofiban displays protective effects in endotoxin induced lung injury. PLoS ONE 11(9):e0161218. https:\/\/doi.org\/10.1371\/journal.pone.0161218","journal-title":"PLoS ONE"},{"key":"3057_CR31","doi-asserted-by":"publisher","unstructured":"Group RC (2022) Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399(10320):143\u2013151. https:\/\/doi.org\/10.1016\/S0140-6736(21)01825-0","DOI":"10.1016\/S0140-6736(21)01825-0"},{"key":"3057_CR32","doi-asserted-by":"publisher","unstructured":"Chow JH et al (2022) Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19. JAMA Netw Open 5(3):e223890. ISSN 2574-3805. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.3890","DOI":"10.1001\/jamanetworkopen.2022.3890"},{"issue":"4","key":"3057_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jacbts.2018.05.005","volume":"3","author":"TR Sexton","year":"2018","unstructured":"Sexton TR et al (2018) Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl Sci 3(4):435\u2013449. https:\/\/doi.org\/10.1016\/j.jacbts.2018.05.005","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"3057_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/ehjcvp\/pvaa099","volume":"8","author":"JH Butt","year":"2022","unstructured":"Butt JH et al (2022) Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections. Eur Heart J Cardiovasc Pharmacother 8(1):13\u201319. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa099","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3057_CR35","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2147\/JEP.S330776","volume":"13","author":"US Tantry","year":"2021","unstructured":"Tantry US et al (2021) Aspirin as an adjunctive pharmacologic therapy option for COVID-19: anti-inflammatory, antithrombotic, and antiviral effects all in one agent. J Exp Pharmacol 13:957\u2013970. https:\/\/doi.org\/10.2147\/JEP.S330776","journal-title":"J Exp Pharmacol"},{"issue":"3","key":"3057_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jama.2021.23605","volume":"327","author":"JS Berger","year":"2022","unstructured":"Berger JS et al (2022) Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial. JAMA 327(3):227\u2013236. https:\/\/doi.org\/10.1001\/jama.2021.23605","journal-title":"JAMA"},{"key":"3057_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.phrs.2016.08.008","volume":"123","author":"AA Manfredi","year":"2017","unstructured":"Manfredi AA, Rovere-Querini P, D\u2019Angelo A, Maugeri N (2017) Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps. Pharmacol Res 123:146\u2013156. https:\/\/doi.org\/10.1016\/j.phrs.2016.08.008","journal-title":"Pharmacol Res"},{"issue":"36","key":"3057_CR38","doi-asserted-by":"publisher","first-page":"15880","DOI":"10.1073\/pnas.1005743107","volume":"107","author":"TA Fuchs","year":"2010","unstructured":"Fuchs TA et al (2010) Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 107(36):15880\u201315885. https:\/\/doi.org\/10.1073\/pnas.1005743107","journal-title":"Proc Natl Acad Sci USA"},{"key":"3057_CR39","doi-asserted-by":"publisher","first-page":"102925","DOI":"10.1016\/j.ebiom.2020.102925","volume":"58","author":"M Leppkes","year":"2020","unstructured":"Leppkes M et al (2020) Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 58:102925. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102925","journal-title":"EBioMedicine"},{"key":"3057_CR40","doi-asserted-by":"publisher","unstructured":"Saithong S et al. Anti-inflammatory effects and decreased formation of neutrophil extracellular traps by enoxaparin in COVID-19 patients. https:\/\/doi.org\/10.3390\/ijms23094805.","DOI":"10.3390\/ijms23094805"},{"issue":"2","key":"3057_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.pupt.2012.01.006","volume":"25","author":"RA Brown","year":"2012","unstructured":"Brown RA et al (2012) Effects of heparin and related drugs on neutrophil function. Pulm Pharmacol Ther 25(2):185\u2013192. https:\/\/doi.org\/10.1016\/j.pupt.2012.01.006","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"3057_CR42","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41467-019-09160-7","volume":"10","author":"J Perdomo","year":"2019","unstructured":"Perdomo J et al (2019) Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun 10(1):1322. https:\/\/doi.org\/10.1038\/s41467-019-09160-7","journal-title":"Nat Commun"},{"issue":"10291","key":"3057_CR43","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","volume":"397","author":"RD Lopes","year":"2021","unstructured":"Lopes RD et al (2021) Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 397(10291):2253\u20132263. https:\/\/doi.org\/10.1016\/S0140-6736(21)01203-4","journal-title":"Lancet"},{"key":"3057_CR44","doi-asserted-by":"publisher","unstructured":"Sadeghipour P et al (2021) Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 325(16):1620\u20131630. https:\/\/doi.org\/10.1001\/jama.2021.4152","DOI":"10.1001\/jama.2021.4152"},{"issue":"4","key":"3057_CR45","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/CCM.0b013e31819c06bc","volume":"37","author":"F Jaimes","year":"2009","unstructured":"Jaimes F et al (2009) Unfractioned heparin for treatment of sepsis: a randomized clinical trial (the HETRASE study). Crit Care Med 37(4):1185\u20131196. https:\/\/doi.org\/10.1097\/CCM.0b013e31819c06bc","journal-title":"Crit Care Med"},{"key":"3057_CR46","doi-asserted-by":"publisher","first-page":"n2400","DOI":"10.1136\/bmj.n2400","volume":"375","author":"M Sholzberg","year":"2021","unstructured":"Sholzberg M et al (2021) Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 375:n2400. https:\/\/doi.org\/10.1136\/bmj.n2400","journal-title":"BMJ"},{"issue":"12","key":"3057_CR47","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","volume":"181","author":"AC Spyropoulos","year":"2021","unstructured":"Spyropoulos AC et al (2021) Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med 181(12):1612\u20131620. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6203","journal-title":"JAMA Intern Med"},{"issue":"2","key":"3057_CR48","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.290.2.238","volume":"290","author":"E Abraham","year":"2003","unstructured":"Abraham E et al (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2):238\u2013247. https:\/\/doi.org\/10.1001\/jama.290.2.238","journal-title":"JAMA"},{"issue":"9","key":"3057_CR49","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1111\/jth.15450","volume":"19","author":"US Perepu","year":"2021","unstructured":"Perepu US et al (2021) Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial. J Thromb Haemost 19(9):2225\u20132234. https:\/\/doi.org\/10.1111\/jth.15450","journal-title":"J Thromb Haemost"},{"issue":"22","key":"3057_CR50","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","volume":"366","author":"VM Ranieri","year":"2012","unstructured":"Ranieri VM et al (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366(22):2055\u20132064. https:\/\/doi.org\/10.1056\/NEJMoa1202290","journal-title":"N Engl J Med"},{"issue":"15","key":"3057_CR51","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","volume":"286","author":"BL Warren","year":"2001","unstructured":"Warren BL et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286(15):1869\u20131878. https:\/\/doi.org\/10.1001\/jama.286.15.1869","journal-title":"JAMA"},{"issue":"12","key":"3057_CR52","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1055\/s-0040-1720978","volume":"120","author":"HH Billett","year":"2020","unstructured":"Billett HH et al (2020) Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 120(12):1691\u20131699. https:\/\/doi.org\/10.1055\/s-0040-1720978","journal-title":"Thromb Haemost"},{"issue":"9","key":"3057_CR53","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","volume":"385","author":"PR Lawler","year":"2021","unstructured":"Lawler PR et al (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 385(9):790\u2013802. https:\/\/doi.org\/10.1056\/NEJMoa2105911","journal-title":"N Engl J Med"},{"key":"3057_CR54","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1136\/bmj.n2400","volume":"375","author":"M Sholzberg","year":"2001","unstructured":"Sholzberg M et al (2001) Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 375:2400. https:\/\/doi.org\/10.1136\/bmj.n2400","journal-title":"BMJ"},{"issue":"9","key":"3057_CR55","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2103417","volume":"385","author":"EC Goligher","year":"2021","unstructured":"Goligher EC et al (2021) Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med 385(9):777\u2013789. https:\/\/doi.org\/10.1056\/NEJMoa2103417","journal-title":"N Engl J Med"},{"issue":"7","key":"3057_CR56","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1538-7836.2009.03455.x","volume":"7","author":"D Varga-Szabo","year":"2009","unstructured":"Varga-Szabo D, Braun A, Nieswandt B (2009) Calcium signaling in platelets. J Thromb Haemost 7(7):1057\u20131066. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03455.x","journal-title":"J Thromb Haemost"},{"issue":"5","key":"3057_CR57","doi-asserted-by":"publisher","first-page":"e97088","DOI":"10.1371\/journal.pone.0097088","volume":"9","author":"AK Gupta","year":"2014","unstructured":"Gupta AK et al (2014) Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine A. PLoS ONE 9(5):e97088. https:\/\/doi.org\/10.1371\/journal.pone.0097088","journal-title":"PLoS ONE"},{"issue":"1","key":"3057_CR58","doi-asserted-by":"publisher","first-page":"a004143","DOI":"10.1101\/cshperspect.a004143","volume":"3","author":"ML Halls","year":"2011","unstructured":"Halls ML, Cooper DM (2011) Regulation by Ca2+-signaling pathways of adenylyl cyclases. Cold Spring Harb Perspect Biol 3(1):a004143. https:\/\/doi.org\/10.1101\/cshperspect.a004143","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3057_CR59","doi-asserted-by":"publisher","first-page":"643560","DOI":"10.3389\/fpls.2021.643560","volume":"12","author":"B \u015awie\u017cawska-Boniecka","year":"2021","unstructured":"\u015awie\u017cawska-Boniecka B et al (2021) Cross talk between cyclic nucleotides and calcium signaling pathways in plants-achievements and prospects. Front Plant Sci 12:643560. https:\/\/doi.org\/10.3389\/fpls.2021.643560","journal-title":"Front Plant Sci"},{"key":"3057_CR60","unstructured":"Pirahanchi Y, Dimri M (2023) Biochemistry, guanylate cyclase. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC"},{"issue":"9","key":"3057_CR61","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","volume":"14","author":"M Gheorghiade","year":"2012","unstructured":"Gheorghiade M et al (2012) Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 14(9):1056\u20131066. https:\/\/doi.org\/10.1093\/eurjhf\/hfs093","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"3057_CR62","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1161\/01.hyp.0000036027.71527.3e","volume":"40","author":"C Schalcher","year":"2002","unstructured":"Schalcher C et al (2002) Interaction of sildenafil with cAMP-mediated vasodilation in vivo. Hypertension 40(5):763\u2013767. https:\/\/doi.org\/10.1161\/01.hyp.0000036027.71527.3e","journal-title":"Hypertension"},{"key":"3057_CR63","doi-asserted-by":"publisher","unstructured":"Evans N, Seri I, Kluckow M (2019) Chapter 29\u2014Hemodynamically based pharmacologic management of circulatory compromise in the newborn. In: Hemodynamics and cardiology, 3rd edn. Elsevier, Philadelphia, pp 521\u2013534. https:\/\/doi.org\/10.1016\/B978-0-323-53366-9.00029-6","DOI":"10.1016\/B978-0-323-53366-9.00029-6"},{"key":"3057_CR64","doi-asserted-by":"publisher","unstructured":"Rosa PVF et al (2019) BAY 41-2272 inhibits human neutrophil functions. Elsevier B.V. https:\/\/doi.org\/10.1016\/j.intimp.2019.105767","DOI":"10.1016\/j.intimp.2019.105767"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03057-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:24:51Z","timestamp":1741307091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03057-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3057"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03057-z","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"30 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"During the preparation of this work the author(s) used  in order to correct grammatical errors in the text. After using this tool, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}},{"value":"The study was conducted in compliance with the Helsinki Declaration. A waiver of the Informed Consent was granted based on the emergence of the pandemic, the observational nature of the study, the utilization of data obtained from medical records, and the use of residual samples. The study ensured the deidentification of patient records. In addition, patients diagnosed with COVID-19 were isolated, and access to the patients and their relatives was restricted to healthcare personnel.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}